Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Synthroid market share "holding steady"

Executive Summary

Synthroid "monthly market share continues to hold steady and market growth remains healthy in the high single digits," Abbott VP-Investor Relations & Public Affairs Catherine Babington said. Third quarter sales were $216 mil., up from $166 mil. in the previous quarter. The levothyroxine product "reported unusually strong third-quarter sales due in part to trade and patient stocking." FDA is requiring Abbott to phase-down its distribution of Synthroid while the NDA, submitted Aug. 1, is pending at the agency (1"The Pink Sheet" July 16, p. 16)
Advertisement

Related Content

Advertisement
UsernamePublicRestriction

Register

PS038685

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel